|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZBED2 |
Gene summary for ZBED2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZBED2 | Gene ID | 79413 |
| Gene name | zinc finger BED-type containing 2 | |
| Gene Alias | ZBED2 | |
| Cytomap | 3q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9BTP6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79413 | ZBED2 | P5T-E | Human | Esophagus | ESCC | 3.16e-11 | 4.34e-01 | 0.1327 |
| 79413 | ZBED2 | P10T-E | Human | Esophagus | ESCC | 8.19e-04 | 1.31e-01 | 0.116 |
| 79413 | ZBED2 | P21T-E | Human | Esophagus | ESCC | 1.20e-15 | 6.77e-01 | 0.1617 |
| 79413 | ZBED2 | P22T-E | Human | Esophagus | ESCC | 1.21e-16 | 4.33e-01 | 0.1236 |
| 79413 | ZBED2 | P31T-E | Human | Esophagus | ESCC | 1.49e-02 | 1.97e-01 | 0.1251 |
| 79413 | ZBED2 | P49T-E | Human | Esophagus | ESCC | 2.05e-04 | 1.19e+00 | 0.1768 |
| 79413 | ZBED2 | P52T-E | Human | Esophagus | ESCC | 8.98e-04 | 2.90e-01 | 0.1555 |
| 79413 | ZBED2 | P74T-E | Human | Esophagus | ESCC | 7.50e-11 | 2.81e-01 | 0.1479 |
| 79413 | ZBED2 | P83T-E | Human | Esophagus | ESCC | 3.25e-06 | 5.15e-01 | 0.1738 |
| 79413 | ZBED2 | P91T-E | Human | Esophagus | ESCC | 1.78e-10 | 1.61e+00 | 0.1828 |
| 79413 | ZBED2 | P107T-E | Human | Esophagus | ESCC | 1.80e-21 | 1.06e+00 | 0.171 |
| 79413 | ZBED2 | P126T-E | Human | Esophagus | ESCC | 1.20e-02 | 2.17e-01 | 0.1125 |
| 79413 | ZBED2 | C04 | Human | Oral cavity | OSCC | 6.48e-17 | 9.77e-01 | 0.2633 |
| 79413 | ZBED2 | C21 | Human | Oral cavity | OSCC | 3.92e-15 | 7.76e-01 | 0.2678 |
| 79413 | ZBED2 | C30 | Human | Oral cavity | OSCC | 8.33e-19 | 9.82e-01 | 0.3055 |
| 79413 | ZBED2 | C06 | Human | Oral cavity | OSCC | 2.27e-02 | 1.05e+00 | 0.2699 |
| 79413 | ZBED2 | SYSMH2 | Human | Oral cavity | OSCC | 1.18e-02 | 2.09e-01 | 0.2326 |
| 79413 | ZBED2 | SYSMH3 | Human | Oral cavity | OSCC | 8.13e-07 | 2.49e-01 | 0.2442 |
| 79413 | ZBED2 | SYSMH5 | Human | Oral cavity | OSCC | 4.80e-04 | 1.88e-01 | 0.0647 |
| 79413 | ZBED2 | P1_cSCC | Human | Skin | cSCC | 7.55e-04 | 2.09e-01 | 0.0292 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00435888 | Esophagus | ESCC | skin development | 163/8552 | 263/18723 | 6.48e-08 | 1.14e-06 | 163 |
| GO:000854410 | Esophagus | ESCC | epidermis development | 193/8552 | 324/18723 | 2.87e-07 | 4.19e-06 | 193 |
| GO:000991310 | Esophagus | ESCC | epidermal cell differentiation | 122/8552 | 202/18723 | 1.69e-05 | 1.51e-04 | 122 |
| GO:00456826 | Esophagus | ESCC | regulation of epidermis development | 46/8552 | 65/18723 | 3.65e-05 | 2.97e-04 | 46 |
| GO:00302167 | Esophagus | ESCC | keratinocyte differentiation | 86/8552 | 139/18723 | 8.53e-05 | 6.19e-04 | 86 |
| GO:00456046 | Esophagus | ESCC | regulation of epidermal cell differentiation | 41/8552 | 58/18723 | 1.00e-04 | 7.10e-04 | 41 |
| GO:00456167 | Esophagus | ESCC | regulation of keratinocyte differentiation | 26/8552 | 37/18723 | 2.16e-03 | 9.62e-03 | 26 |
| GO:00456841 | Esophagus | ESCC | positive regulation of epidermis development | 23/8552 | 32/18723 | 2.43e-03 | 1.06e-02 | 23 |
| GO:00456061 | Esophagus | ESCC | positive regulation of epidermal cell differentiation | 20/8552 | 27/18723 | 2.61e-03 | 1.11e-02 | 20 |
| GO:00456181 | Esophagus | ESCC | positive regulation of keratinocyte differentiation | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
| GO:00435887 | Oral cavity | OSCC | skin development | 143/7305 | 263/18723 | 2.77e-07 | 4.27e-06 | 143 |
| GO:00085449 | Oral cavity | OSCC | epidermis development | 171/7305 | 324/18723 | 2.89e-07 | 4.43e-06 | 171 |
| GO:00302166 | Oral cavity | OSCC | keratinocyte differentiation | 81/7305 | 139/18723 | 3.16e-06 | 3.81e-05 | 81 |
| GO:00099139 | Oral cavity | OSCC | epidermal cell differentiation | 109/7305 | 202/18723 | 1.08e-05 | 1.14e-04 | 109 |
| GO:00456825 | Oral cavity | OSCC | regulation of epidermis development | 41/7305 | 65/18723 | 7.29e-05 | 5.73e-04 | 41 |
| GO:00456045 | Oral cavity | OSCC | regulation of epidermal cell differentiation | 36/7305 | 58/18723 | 3.15e-04 | 1.96e-03 | 36 |
| GO:00456166 | Oral cavity | OSCC | regulation of keratinocyte differentiation | 23/7305 | 37/18723 | 3.66e-03 | 1.51e-02 | 23 |
| GO:0045684 | Oral cavity | OSCC | positive regulation of epidermis development | 20/7305 | 32/18723 | 6.05e-03 | 2.28e-02 | 20 |
| GO:0045618 | Oral cavity | OSCC | positive regulation of keratinocyte differentiation | 13/7305 | 19/18723 | 9.07e-03 | 3.26e-02 | 13 |
| GO:0045606 | Oral cavity | OSCC | positive regulation of epidermal cell differentiation | 17/7305 | 27/18723 | 1.01e-02 | 3.49e-02 | 17 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZBED2 | SNV | Missense_Mutation | c.277G>T | p.Val93Leu | p.V93L | Q9BTP6 | protein_coding | tolerated(0.07) | possibly_damaging(0.497) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| ZBED2 | SNV | Missense_Mutation | rs139937578 | c.361N>T | p.Arg121Cys | p.R121C | Q9BTP6 | protein_coding | deleterious(0.03) | benign(0) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ZBED2 | SNV | Missense_Mutation | c.315N>A | p.Met105Ile | p.M105I | Q9BTP6 | protein_coding | tolerated(0.21) | possibly_damaging(0.61) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZBED2 | SNV | Missense_Mutation | novel | c.572T>C | p.Met191Thr | p.M191T | Q9BTP6 | protein_coding | tolerated(0.18) | benign(0.007) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZBED2 | SNV | Missense_Mutation | c.16N>T | p.Asp6Tyr | p.D6Y | Q9BTP6 | protein_coding | deleterious_low_confidence(0) | benign(0.424) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ZBED2 | SNV | Missense_Mutation | rs138334089 | c.536G>A | p.Arg179Gln | p.R179Q | Q9BTP6 | protein_coding | tolerated(0.27) | benign(0.001) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| ZBED2 | deletion | Frame_Shift_Del | c.529delA | p.Arg177GlyfsTer15 | p.R177Gfs*15 | Q9BTP6 | protein_coding | TCGA-AA-A01I-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| ZBED2 | SNV | Missense_Mutation | novel | c.34N>C | p.Thr12Pro | p.T12P | Q9BTP6 | protein_coding | deleterious_low_confidence(0.03) | benign(0.029) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ZBED2 | SNV | Missense_Mutation | rs186768110 | c.382G>A | p.Gly128Arg | p.G128R | Q9BTP6 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AJ-A3BG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
| ZBED2 | SNV | Missense_Mutation | rs376107359 | c.508N>T | p.Arg170Trp | p.R170W | Q9BTP6 | protein_coding | tolerated(0.06) | benign(0.009) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |